|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1991-12-26
|
|
pubmed:abstractText |
1 Perindopril is a prodrug which is hydrolysed in vivo to the active metabolite perindoprilat, an angiotensin-converting enzyme inhibitor. Perindoprilat glucuronide is also found in plasma. 2 The pharmacokinetics of perindopril and its metabolites were studied after administration of a single 4 mg dose to hypertensive patients with various degrees of renal failure. 3 The absorption and elimination of perindopril were not influenced by the degree of renal failure. 4 The mean area under the serum concentration-time curve of the active metabolite perindoprilat increased from 93 ng ml-1 h in subjects with normal renal function to 1106 ng ml-1 in patients with severe renal failure, whereas its half-life varied from 5.0 to 27.4 h. 5 In the same subjects, the mean area under the curve of perindoprilat glucuronide increased from 78 to 513 ng ml-1 h, while its half-life varied from 1.8 h to 7.7 h. 6 Perindopril, perindoprilat, and perindoprilat glucuronide were dialysable. 7 The extent and duration of serum angiotensin-converting enzyme inhibition was augmented in renal failure. The mean area under the inhibition time curve (extrapolated to infinity) increased from 2490%.h in subjects with normal renal function to 42241 %.h in patients with severe renal impairment. The half-life of inhibition varied from 12.1 h to 100.4 h. This effect of renal failure on the pharmacodynamics of perindoprilat was more pronounced than its influence on perindoprilat kinetics. 8 In view of the important influence of renal impairment on the elimination and action of the active substance perindoprilat, a dosage reduction of perindopril is proposed in in patients with renal failure.(ABSTRACT TRUNCATED AT 250 WORDS)
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-2231339,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-2351367,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-2844467,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-2893876,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-2998676,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-3004546,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-3034037,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-3034622,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-3061819,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-6084763,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-6095887,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-6317227,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-6381858,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1657092-6757976
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0306-5251
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
187-92
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:1657092-Adult,
pubmed-meshheading:1657092-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:1657092-Blood Pressure,
pubmed-meshheading:1657092-Female,
pubmed-meshheading:1657092-Glucuronates,
pubmed-meshheading:1657092-Half-Life,
pubmed-meshheading:1657092-Humans,
pubmed-meshheading:1657092-Hypertension, Renal,
pubmed-meshheading:1657092-Indoles,
pubmed-meshheading:1657092-Kidney Failure, Chronic,
pubmed-meshheading:1657092-Male,
pubmed-meshheading:1657092-Middle Aged,
pubmed-meshheading:1657092-Peptidyl-Dipeptidase A,
pubmed-meshheading:1657092-Perindopril,
pubmed-meshheading:1657092-Renal Dialysis
|
|
pubmed:year |
1991
|
|
pubmed:articleTitle |
Single dose pharmacokinetics of perindopril and its metabolites in hypertensive patients with various degrees of renal insufficiency.
|
|
pubmed:affiliation |
Department of Nephrology-Hypertension, University of Antwerp, Edegem, Belgium.
|
|
pubmed:publicationType |
Journal Article
|
